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Diabetes has become the epidemic of the 21st century, and with over 90% patients with diabetes becoming at a risk of devel-
oping retinopathy, diabetic retinopathy has emerged as a major public health concern. In spite of cutting edge research in the 
field, how retina and its vasculature are damaged by the diabetic milieu remains ambiguous. The environmental factors, life 
style or disease process can also bring in modifications in the DNA, and these epigenetic modifications either silence or acti-
vate a gene without altering the DNA sequence. Diabetic environment up- or downregulates a number of genes in the retina, 
and emerging research has shown that it also facilitates epigenetic modifications. In the pathogenesis of diabetic retinopathy, 
the genes associated with important enzymes (e.g., mitochondrial superoxide dismutase, matrix metalloproteinase-9 and thi-
oredoxin interacting protein) and transcriptional factors are epigenetically modified, the enzymes responsible for these epige-
netic modifications are either activated or inhibited, and the levels of microRNAs are altered. With epigenetic modifications 
taking an important place in diabetic retinopathy, it is now becoming critical to evaluate these modifications, and understand 
their impact on this slow progressing blinding disease. 
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Diabetic retinopathy is the most feared complication as over 
90% of the patients with diabetes for more than 20 years 
encounter some symptoms of retinopathy. With the number 
of diabetes increasing at an alarming rate, the number of 
people with retinopathy is expected to increase from 126.6 
million in 2011 to 191 million by 2030, and the vi-
sion-threatening retinopathy during this period will increase 
from 37.3 million to 56.3 million [1]. Due to high circulat-
ing glucose, the tiny blood vessels that nourish the retina are 
damaged, and in the early stages of the disease, microaneu-
rysms, hemorrhages, intra-retinal microvascular abnormali-
ties result in bleeding. If not controlled, this non-prolifera- 
tive stage could progress to proliferative stage where the 
new vessels begin to grow, ultimately resulting in retinal 
detachment and blindness [2]. 
The pathogenesis of diabetic retinopathy is complex; 
although hyperglycemia is considered as the leading cause 
of the development of diabetic retinopathy, however, hy-
pertension and dyslipidemia are also some of the major risk 
factors associated with the disease [35]. A number of 
metabolic abnormalities initiated by hyperglycemia are im-
plicated in the development of diabetic retinopathy. Oxida-
tive stress is regarded as one of the leading mechanisms in 
its development, and increase in oxidative stress in diabetic 
milieu is associated with a number of other interlinking 
metabolic abnormalities including the accumulation of ad-
vanced glycation end products, activation of protein kinase 
C, polyol and hexosamine pathways [2,68]. Though many 
leading laboratories are involved in cutting edge research to 
understand the etiology of this complex disease, the exact 
mechanism responsible for its development remains elusive.  
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1  Genetics and diabetic retinopathy 
In addition to metabolic and physiologic factors, pathogen-
esis of a disease is also influenced by genetic factors. Due to 
variability in the severity of retinopathy among patients 
with diabetes with similar risk factors, however, genetic 
associations with diabetic retinopathy remain unclear. Ge-
nome-wide association studies have identified a number of 
genetic variants that could explain some of the in-
ter-individual variations in the susceptibility of diabetes. A 
meta-analysis study has shown a significant variation in the 
AKR1B1gene, a gene encoding aldo-keto reductase family 1 
member B1, and this rate limiting enzyme of the polyol 
pathway is strongly associated with diabetic retinopathy [9]. 
Another meta-analysis study with patients with type 2 dia-
betes has shown a protective role of Pro12Ala polymor-
phism in the peroxisome proliferator-activated receptor-γ2 
gene in the incidence of retinopathy [10]. In contrast, recent 
studies have failed to find any associations between vascu-
lar endothelial growth factor (VEGF)-related single nucleo-
tide polymorphisms (rs6921438 and rs10738760) and the 
risk of retinopathy and nephropathy in patients with diabe-
tes [11]. Thus, the association between genetic factors and 
diabetic retinopathy needs further investigation. 
2  Epigenetics and gene regulation 
Epigenetics is now emerging as one of the important factors 
in many diseases as it can regulate the complex interplay 
between genes and the environment, and these heritable 
changes can occur without any change in the DNA se-
quence. Epigenetic change is a regular and natural phe-
nomenon, and can also be influenced by several factors in-
cluding age, the environment, lifestyle and disease state 
[12,13]. Epigenetic modifications can act like switches 
helping to control gene activity and allowing alternations in 
genome function without altering the gene sequences. At 
least three major epigenetic modifications including DNA 
methylation, histone modification and non-coding RNA are 
considered to initiate and sustain changes in gene regulation 
[14,15]. 
DNA is not a static, fixed entity, but instead it is   
‘highly dynamic’, and it responds to the environmental 
stimuli by modifying its properties in adapting to the 
changes [16]. Methylation of cytosine to 5-methyl cytosine 
(5mC) is considered as one of the major epigenetic modifi-
cation; methylation of the CpG islands, a CG rich region in 
the promoter of many genes, changes protein-DNA interac-
tions leading to alterations in chromatin structure, and this 
interferes with the binding of transcriptional machinery, 
resulting in gene suppression [17,18]. The hypomethylated 
DNA re-activates the repetitive genomic sequences, result-
ing in chromosomal instability and abnormal gene expres- 
sion [19,20]. DNA methylation is catalyzed by DNA methyl 
transferases (Dnmts), a family with five members—Dnmt1, 
Dnmt2, Dnmt3a, Dnmt3b and Dnmt3L; out of which only 
Dnmt1, Dnmt3a and Dnmt3b are catalytically active. 
Dnmt3a and Dnmt3b are de novo methyltransferases, and 
Dnmt1 is a maintenance enzyme important in regulating 
tissue-specific patterns of methylated cytosine residues 
[21,22]. Pathological Dnmt activity and aberrant 5mC for-
mation have been linked with neurodegeneration [23]. 5mC 
can be oxidized to 5-hydroxymethylcytosine (5hmC) by 
ten-eleven translocation enzymes, and 5hmC can also be 
further oxidized to generate 5-formylcytosine and 
5-carboxylcytosine [24]. A subfamily of DNA glycosylases 
are considered to promote active DNA demethylation by 
removing the 5-methylcytosine base, followed by cleavage 
of the DNA backbone at the abasic site, and the methylated 
cytosine is replaced by an unmethylated cytosine [25]. In 
contrast, the passive process involves absence/inactivation 
of Dnmt1 resulting hypomethylated DNA [26]. 
Chromatin, a composite structure of histones and nu- 
cleic acid, instructs the expression pattern of different genes, 
and conformational changes in the DNA, by altering the 
binding of transcription factors and its machinery, can 
change the gene expression. Among the 4-histone proteins, 
histone 2 (H2) exists in 2-subtypes, H2A and H2B which 
along with H3 and H4 forms a tetrameric structure, wrapped 
with 146 bp of nucleic acid [27]. This sophisticated DNA 
packaging still allows N-terminal sequences of histones to 
undergo modifications including acetylation, methylation 
and phosphorylation. These modifications can either open 
or restrict access to DNA by directly altering the electro-
static potential and/or the structure of the local chromatin 
environment or indirectly alter the recruitment of the effec-
tor proteins [28]. Histone modifications are regulated by a 
balance between the enzymes inserting or removing a group 
[29,30]. Acetylation of histones is one of the most common 
modifications; acetylation opens up the chromatin structure, 
which allows recruitment and binding of the transcription 
factor and RNA polymerase II [31]. A group of enzymes 
with opposing functions maintain the required acetylation 
status, while histone acetyltransferases (HATs) inserts an 
acetyl group on a lysine of the histone; histone deacetylases 
(HDACs) remove the acetyl group [29]. In contrast to acet-
ylation, methylation of histone, depending on the target site, 
can turns “off” or “on” the genes [32]. While trimethylation 
of histone H3 at lysine 4 (H3K4me3) is generally consid-
ered as an active mark for transcription, dimethylation of 
histone H3 at lysine 9 (H3K9me2) as a transcriptional si-
lencing mark.  In addition, depending on the degree of res-
idue methylation, different functions can be expected; 
monomethylated H4K20 (H4K20me1) and H4K20me3 are 
considered as transcriptional repressors, H4K20me2 is 
largely considered as an activator [3235]. Histone methyl-
transferases (HMT) catalyze the transfer of one, two, or 
three methyl groups to lysine (and arginine) residues of his-
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tone proteins. There are two major types of HMTs, ly-
sine-specific, which can be SET (Su(var)3-9, Enhancer of 
Zeste, Trithorax) domain containing or non-SET domain 
containing. Contrary to a relatively well defined histone 
methylating system, histone demethylation machinery is not 
well studied; LSD1, a lysine-specific histone demethylase, 
specifically removes methyl group from H3K4me and 
H3K9me [36,37]. 
Recent studies have shown that DNA methylation and 
histone modifications could function in concordance [38]; 
for example, Dnmt1, methyl CpG binding protein 2 (MeCP2) 
and methyl-CpG-binding domain proteins (MBDs) could 
associate with HDAC (39) or CpG methylation could coop-
erate with euchromatic histone methyltransferase 
SETDB1/ESET in histone H3 lysine 9 trimethylation, re-
sulting in gene regulation. In addition, histone modifying 
enzymes, SUV39h1 and EZH2 lysine histone methyltrans-
ferases can interact with Dnmt and regulate their functions 
[4042], and PRMT5-mediated methylation of arginine 
could silence gene expression via recruiting Dnmt3A [43]. 
Thus, both histone modification and DNA methylation 
could regulate the same gene. Although these epigenetic 
modifications do not have to be permanent, their response to 
the changing environment, and passing to the successive 
generations, makes them one of the most important drug 
targets for a chronic disease like diabetic retinopathy. 
Small noncoding RNAs (~22 nucleotides) are also con-
sidered to regulate gene expression as these microRNAs 
(miRNA) bind to the complementary sequences in the 3′ 
untranslated region of mRNAs, and cleave mRNA resulting 
in decreased protein synthesis and expression of the targeted 
gene [44,45]. Methylation of DNA and histone, and miRNA 
appear to work in concordance as the function of Dnmts 
depends on histone modification patterns, such as H3K9 
methylation and histone deacetylation and inhibition of 
Dnmts reactivates some of the miRNAs [46]. Since these 
epigenetic modifications are mainly caused by the local 
environment and can be passed on to the next generation, 
they are now being considered as some of the attractive tar-
gets for chronic disease, including diabetes and cancer [47]. 
3  Epigenetic modification and diabetes 
Glucose is critically important for the organisms for surviv-
al, but sustained levels of high glucose are detrimental, and 
can initiate a number of metabolic, biochemical and genetic 
abnormalities. It affects regulation of genes throughout the 
body. Recent work has suggested that diabetic milieu favors 
epigenetic modifications in various organs associated with 
micro- and macro-vascular complications [8,48,49]. Ge-
nome-wide DNA methylation study using blood cells from 
patients with type 1 diabetes has identified 19 potential CpG 
sites that are prone to DNA methylation in diabetes. 
S-Adenosyl methionine (SAM), the donor of methyl group 
for DNA methylation, is shown to influence the expression 
of genes related with diabetic complications, and blood de-
ficiency of SAM is reported in the patients with diabetic 
nephropathy [5053], and leukocytes from diabetic patients 
have reduced Dnmts levels [54]. Global hypomethylation 
and reduced level of SAM are also observed in Zebrafish 
with chemically induced diabetes [55]. In contrast, in Zuck-
er fatty rat, a model of type 2 diabetes, sustained global 
DNA hypermethylation is observed in the liver, and this is 
associated with abnormal metabolism of the methyl group 
[53]. These divergent patterns of DNA methylation in dia-
betes suggest that various tissues could be responding dif-
ferently to diabetes. 
Hyperglycemia is also associated with aberrant changes 
in H3K4me2 and H3K9me2 in human monocytic THP-1 
cells and increases histone acetylation in the chromatin re-
gion containing the promoter of the transcription factor, 
nuclear factor kappa B (NF-B)-p65 [56]. In vascular 
smooth muscle cells derived from type 2 diabetic mice, ir-
reversibly decreased levels of both H3K9me3 and methyl-
transferase Suv39H1 at the promoters of interleukin-6 and 
monocyte chemoattractant protein1 are observed, and 
SUV39H1 gene silencing irreversibly elevates the expres-
sion of inflammatory genes and decreases H3K9me3 at their 
promoters [57]. Monocytes from case subjects enrolled   
in landmark the Diabetes Control and Complications Trial 
and the follow up Epidemiology of Diabetes Interven-  
tions and Complications study have shown a significant 
association between H3K9 acetylation and hemoglobin A1C 
levels [58].  
In addition to histone modifications and DNA methyla-
tion, miRNAs are also associated with various diabetic 
complications. Increased levels of miR-377 and miR-21 are 
observed in the human and mouse mesangial cells exposed 
to hyperglycemic milieu [59,60]. Increased miR-377 levels 
have been linked to the induction of fibronectin, which con-
tributes to the renal fibrosis in hyperglycemia [59]. Glu-
cose-induced miR-146a downregulation is mediated 
through the HAT p300, suggesting an interrelationship be-
tween histone acetylation and miR-146a mediated fibron-
ectin expression and a possible functional link between 
miRNA expression and histone modification in diabetes 
[61]. Thus, epigenetic modifications appear to play an im-
portant role in the development of diabetes and its compli-
cations. 
4  Epigenetic modification in diabetic retinopa-
thy 
Diabetic retinopathy, a slow progressing disease, is associ-
ated with a number of metabolic abnormalities [2,7,8], 
however, the role of epigenetic modifications in diabetic 
retinopathy is still not clear. In a Finnish study, an associa-
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tion between the polymorphism in SUV39H2, a gene that 
encodes histone methyltransferases and microvascular com-
plications, including retinopathy has been observed in pa-
tients with diabetes [62]. In a cross-sectional study with 
over 1,000 patients having type 2 diabetes, analysis of their 
family history has suggested a possible genetic and epige-
netic basis for the development of diabetic retinopathy 
[63,64]. Experimental evidence using in vitro and in vivo 
models of diabetic retinopathy have shown that the activi-
ties of HDACs are increased and that of HATs are de-
creased in the retina and its capillary cells in diabetes, and 
global acetylation of histones is decreased [65]. However, 
contrary to this, others have shown significant increase in 
retinal histone acetylation in diabetes [66]; undermining the 
importance of further investigation into the role of histone 
modifying enzymes in the development of diabetic reti-
nopathy. 
Mitochondrial superoxide are considered as the unifying 
molecules connecting many metabolic abnormalities asso-
ciated with diabetic retinopathy [7,67,68], and in diabetes, 
retinal mitochondria are damaged and superoxide scaveng-
ing enzyme (superoxide dismutase) is dysfunctional [69]. 
We have shown that diabetes epigenetically modifies Sod2, 
the gene encoding mitochondrial superoxide dismutase, and 
H4K20me3, acetyl H3K9 and p65 subunit of NF-B (p65) 
are increased at its promoter/enhancer, H3K4 is demethyl-
ated and LSD1 binding is increased. These results have 
clearly suggested that epigenetic modifications have a major 
role in the regulation of superoxide levels, and thus in the 
development of retinopathy [70,71]. Furthermore, epigenet-
ic modifications are also implicated in the function of Nrf2, 
a master regulator which regulates the expression of stress 
responsive gene. Due to epigenetic modifications at the 
promoter of Kelch-like ECH associated protein 1 (Keap1, 
an intracellular inhibitor of Nrf2), the binding of transcrip-
tional factor Sp1 is increased. This results in increased ex-
pression of Keap1 and Keap1 tries to restrain the redox sen-
sitive transcription factor in the cytosol, impairing its tran-
scriptional activity and increasing oxidative stress. Fur-
thermore, due to increased H3K4me1, Nrf2 binding at its 
glutamate-cysteine ligase-antioxidant response element re-
gion 4 Gclc-ARE4 is decreased, resulting in decreased tran-
scripts of the catalytic subunit of glutamate-cysteine ligase, 
an important enzyme responsible for biosynthesis of the 
intracellular antioxidant, glutathione [7274]. 
In the pathogenesis of diabetic retinopathy, activation of 
matrix metalloproteinase-9 (MMP-9) is shown to damage 
mitochondria, and this initiates the apoptotic machinery 
[75,76]. MMP-9 is regulated by NF-B and the activation of 
NF-B is modulated by the acetylation of its p65 subunit. 
Sirt1, a deacetylase, plays an important role in the acetyla-
tion-deacetylation of p65, and the activity of retinal Sirt1 is 
decreased and the acetylation of p65 is increased in diabetes 
[77]. Consistent with this, retina from human donors with 
diabetic retinopathy have decreased H3K9me2 at MMP-9 
promoter, acetyl H3K9 levels are elevated, and this facili-
tates the recruitment of p65 at its promoter and upregulates 
MMP-9, damaging mitochondria and increasing superoxide 
levels [78]. In addition, epigenetic modifications of thiore-
doxin interacting protein, an endogenous inhibitor of anti-
oxidant thioredoxin, are associated with sustained Cox2 
expression seen in the retina in diabetes [79,80]. 
DNA methylation, an important epigenetic modification, 
is closely associated with the regulation of gene transcrip-
tion [17,18]. A case control study using patients having type 
2 diabetes has shown significantly higher levels of global 
DNA methylation in patients having diabetes with reti-
nopathy compared to those with no retinopathy, and although 
global DNA methylation appears to be independent of reti-
nopathy risk factors, e.g., hyperglycemia, dyslipidemia and 
hypertension, in these patients, the methylation status of 
DNA shows a correlation with the progression of retinopathy 
[63,64]. Experimental studies using in vitro and in vivo 
models of diabetic retinopathy have shown that the regula-
tory region of DNA polymerase gamma, an enzyme im-
portant in mitochondrial DNA biogenesis, is hypermethyl-
ated, and due to increased CpG methylation, its expression 
is reduced and its binding to the regulatory region of 
mtDNA is attenuated, resulting in subnormal mtDNA bio-
genesis [51]. These studies have clearly suggested that both 
the histone modifications and DNA methylation have im-
portant roles in maintaining mitochondrial homeostasis and 
regulating superoxide levels, which has an important role in 
the development of diabetic retinopathy. 
In addition to modifications of histones and DNA, the 
small non-coding RNAs can also regulate post-transcrip- 
tional gene expression by binding to their target messenger 
RNAs, resulting in alterations in gene transcription [44,45]. 
These miRNAs are stable, and this makes them as ideal 
biomarkers in several diseases, including diabetes. Their 
function is somewhat complex as the same miRNA can tar-
get a number of genes, and the same gene can be targeted 
by a number of miRNA [81,82]. Studies with experimental 
models of diabetic retinopathy have revealed a number of 
miRNAs with either increase or decrease in their expres-
sions. Experimental models of diabetic retinopathy have 
shown an association between the downregulation of 
miR-126, miR-146a and miR-200b and upregulation of 
VEGF, and downregulation of miR-146a is also associated 
with fibronectin production, and upregulation of miR-195 
with downregulation of deacetylase Sirt1. Upregulation of 
miR-29b in the early stages of diabetes is considered to be 
protective against apoptosis of the retinal ganglion cells 
[83,84]. These studies have clearly suggested the important 
role for miRNAs in regulating various aspects of diabetic 
retinopathy, including blood retinal breakdown and neo-
vascularization. 
Thus, diabetic environment favors epigenetic modifica-
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tions in the retina; DNA methylation and miRNAs are al-
tered and histones are modified. DNA methylation and his-
tone modifications could also affect miRNA levels. Due to 
epigenetic modifications, the binding of transcription fac-
tors (e.g., NF-B and Nrf2) and the expression of genes 
(Sod2, MMP-9, Keap1, TXNIP, VEGF, etc.) become ab-
normal, resulting in the metabolic, physiological and struc-
tural abnormalities, and the development of diabetic reti-
nopathy (Figure 1, Table 1). 
5  Therapeutic implications 
As mentioned above, epigenetic appears to play a major role 
in the development of diabetic retinopathy. Histone modifi-
cations have an important dynamic role in the regulation of 
gene expression; acetylation status of histones can directly 
influence the transcription of a gene. There is clearly a 
growing interest in the therapeutic use of HDAC inhibitors 
in the treatment of abnormalities in histone acetylases and 
deacetylases. Epigallocatechin-3-gallate is a strong histone 
acetylase inhibitor, and is shown to inhibit NF-B activation 
[85] and in the pathogenesis of diabetic retinopathy, activa-
tion of NF-B is considered to accelerate apoptosis of ca-
pillary cells, suggesting that inhibitor has potential to inhibit 
the development of diabetic retinopathy. Resveratrol, a nat-
urally occurring compound found in grapes, wine and euca-
lyptus, is a potent activator of Sirt1, and it also inhibits some 
histone deacetylases [86]. In addition, curcumin [87] and 
genistein [88] are also shown to activate histone acetylases  
and inhibit deacetylases [89]. Vorinostat (suberanilohy-
droxamic acid), a HDAC inhibitor, is now approved by 
FDA for Cutaneous T-cell lymphoma [90]. As with histone 
acetylating-deacetylating enzymes, histone methyltransfer-
ases are also being considered as targets for therapeutics. 
Enhancer of Zeste Homolog 2 (EZH2), important for 
H3K27 methylation, has been shown to be inhibited by 
3-deazaneplanocin, and specific inhibitors of EZH2, e.g., 
GSK126, seem to be showing promising results for the 
treatment of cancer. Epigenomic-based therapies targeting 
histone modifications are also being developed, and they 
offer new approaches for the treatment of ovarian cancer 
[91]. 
DNA methylation also plays a key role in gene regulation, 
and DNA methyltransferases are the key enzymes for DNA 
methylation. Nucleoside analogs incorporate into the DNA 
and trap all DNA methyltransferases, and the US Food and 
Drug Administration has already approved Dnmt inhibitors 
5-azacytidine (5-Aza-CR; azacitidine; Vidaza) and 5-aza- 
20-deoxycitidine (5-Aza-CdR; decitabine; Dacogen) for 
myeloid cancers and cutaneous T cell lymphoma. Non nu-
cleotide analogue RG108 is now in pre-clinical trials, and 
MG98 in phase I/II clinical trials [92]. VEGF receptor pro-
moter methylation is considered an important factor in de- 
termining the efficacy of the VEGF-targeted drugs on the 
proliferation of cancer tissue [93], and this has tremendous   
Table 1  Epigenetic modifications in diabetic retinopathy 
Enzymes/miRNAs Targets/modifications 
KDM5A, LSD1 Gclc promoter histone modification (H3K4me3, H3K4me1) 
SetD7/9 Keap1 promoter histone modification (H3K4me1) 
LSD1 MMP-9 promoter histone modification (H3K9me2, H3K9-Ac) 
LSD1, SUV420h2 Sod2 promoter histone modification (H3K4me1, H3K4me2, H4K20me3, H3K9-Ac) 
HAT (p300) TXNIP promoter 
Dnmts PolG1 promoter DNA methylation 





Figure 1 (color online)  Sustained hyperglycemic insult results in a number of metabolic (e.g., PKC, AGEs, polyol pathway, oxidative stress), physiological 
(vascular permeability etc.) and structural (capillary cell loss, hemorrhages etc.) abnormalities in the retina that culminate in the development of retinopathy. 
In addition, diabetic environment also favors epigenetic modifications in the histones and DNA, and alters miRNA levels. These epigenetic modifications 
also fuel into the metabolic/physiological/structural abnormalities associated with the pathogenesis of diabetic retinopathy. 
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clinical implications for diabetic retinopathy.  
Since miRNAs are considered as potential diagnostic 
biomarkers for disease, double-stranded miRNA mimics 
and anti-mRNA antisense oligo-deoxyribonucleotide are 
being used to target specific miRNA [84]. Also, since one 
miRNA can have a number of targets, a therapy targeting a 
specific miRNA can also alter other pathways associated 
with the disease [81,82]. However, one of the major caveats 
with the miRNA-based therapy could be their access to the 
posterior part of the eye and trouble with crossing the 
blood-retina barrier. 
As a number of epigenetic modifications are now being 
associated with the development of diabetic retinopathy, 
there is a great potential for therapeutics targeted towards 
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